Stevanato Group SpA (STVN) Reports Strong Q3 Earnings
Stevanato Group SpA (STVN) exceeds Q3 2025 earnings expectations.
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova and currently employs 5,521 full-time employees. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Stevanato Group SpA.
Last Updated: Dec 11, 2025, 11:39 PM · Source: Finnhub.io